193 related articles for article (PubMed ID: 24563617)
1. Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.
Karam M; Thenoz M; Capraro V; Robin JP; Pinatel C; Lancon A; Galia P; Sibon D; Thomas X; Ducastelle-Lepretre S; Nicolini F; El-Hamri M; Chelghoun Y; Wattel E; Mortreux F
Neoplasia; 2014 Jan; 16(1):21-30. PubMed ID: 24563617
[TBL] [Abstract][Full Text] [Related]
2. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
[TBL] [Abstract][Full Text] [Related]
3. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells.
Sinha-Datta U; Horikawa I; Michishita E; Datta A; Sigler-Nicot JC; Brown M; Kazanji M; Barrett JC; Nicot C
Blood; 2004 Oct; 104(8):2523-31. PubMed ID: 15226182
[TBL] [Abstract][Full Text] [Related]
5. Role of human T-cell leukemia virus type I Tax in expression of the human telomerase reverse transcriptase (hTERT) gene in human T-cells.
Hara T; Matsumura-Arioka Y; Ohtani K; Nakamura M
Cancer Sci; 2008 Jun; 99(6):1155-63. PubMed ID: 18422743
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1.
Terme JM; Mocquet V; Kuhlmann AS; Zane L; Mortreux F; Wattel E; Duc Dodon M; Jalinot P
Leukemia; 2009 Nov; 23(11):2081-9. PubMed ID: 19587703
[TBL] [Abstract][Full Text] [Related]
7. Regulation of histone acetyltransferase activity of p300 and PCAF by proto-oncogene protein DEK.
Ko SI; Lee IS; Kim JY; Kim SM; Kim DW; Lee KS; Woo KM; Baek JH; Choo JK; Seo SB
FEBS Lett; 2006 May; 580(13):3217-22. PubMed ID: 16696975
[TBL] [Abstract][Full Text] [Related]
8. The distribution of the DEK protein in mammalian chromatin.
Hu HG; Scholten I; Gruss C; Knippers R
Biochem Biophys Res Commun; 2007 Jul; 358(4):1008-14. PubMed ID: 17524367
[TBL] [Abstract][Full Text] [Related]
9. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene.
Sammons M; Wan SS; Vogel NL; Mientjes EJ; Grosveld G; Ashburner BP
J Biol Chem; 2006 Sep; 281(37):26802-12. PubMed ID: 16829531
[TBL] [Abstract][Full Text] [Related]
11. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.
Fu GK; Grosveld G; Markovitz DM
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1811-5. PubMed ID: 9050861
[TBL] [Abstract][Full Text] [Related]
12.
Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
[TBL] [Abstract][Full Text] [Related]
13. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery.
Gamble MJ; Fisher RP
Nat Struct Mol Biol; 2007 Jun; 14(6):548-55. PubMed ID: 17529993
[TBL] [Abstract][Full Text] [Related]
14. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
15. DEK over-expression promotes mitotic defects and micronucleus formation.
Matrka MC; Hennigan RF; Kappes F; DeLay ML; Lambert PF; Aronow BJ; Wells SI
Cell Cycle; 2015; 14(24):3939-53. PubMed ID: 25945971
[TBL] [Abstract][Full Text] [Related]
16. p300/CBP-associated factor drives DEK into interchromatin granule clusters.
Cleary J; Sitwala KV; Khodadoust MS; Kwok RP; Mor-Vaknin N; Cebrat M; Cole PA; Markovitz DM
J Biol Chem; 2005 Sep; 280(36):31760-7. PubMed ID: 15987677
[TBL] [Abstract][Full Text] [Related]
17. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
[TBL] [Abstract][Full Text] [Related]
18. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of hTERT transcription by Tax.
Gabet AS; Mortreux F; Charneau P; Riou P; Duc-Dodon M; Wu Y; Jeang KT; Wattel E
Oncogene; 2003 Jun; 22(24):3734-41. PubMed ID: 12802280
[TBL] [Abstract][Full Text] [Related]
20. The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes.
McGarvey T; Rosonina E; McCracken S; Li Q; Arnaout R; Mientjes E; Nickerson JA; Awrey D; Greenblatt J; Grosveld G; Blencowe BJ
J Cell Biol; 2000 Jul; 150(2):309-20. PubMed ID: 10908574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
